GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study.

What Was Tested

The paper reports a study of Chorionic Gonadotropin, published as a randomized controlled trial.

The primary objective of this study was to evaluate the incidence of ovarian hyperstimulation syndrome (OHSS) following GnRH agonist versus recombinant human chorionic gonadotrophin (HCG) as methods for triggering ovulation.

A second aim was to compare the clinical outcome and embryo quality according to the two procedures.

Why It Was Studied

The use of gonadotrophin-releasing hormone (GnRH) agonists for triggering ovulation remains controversial.

The cycle characteristics of 100 oocyte donors undergoing ovarian stimulation and IVF outcomes of their 100 oocyte recipients were analysed.

Who Took Part

By PubMed's age tags, the people studied were teenagers and adults, women only.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Chorionic Gonadotropin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

The cycle characteristics of 100 oocyte donors undergoing ovarian stimulation and IVF outcomes of their 100 oocyte recipients were analysed.

The subject headings attached to it are Chorionic Gonadotropin, Fertilization in Vitro, Gonadotropin-Releasing Hormone, Oocyte Donation, Ovarian Hyperstimulation Syndrome, Ovulation Induction and Recombinant Proteins.

What This Means in Plain Language

The paper is a randomized study of Chorionic Gonadotropin.

The publication is from 2009 (Reproductive biomedicine online), a journal based in Netherlands.

More context: the related hCG (human chorionic gonadotropin) library page, all human trials.